NeuroPace (NPCE) News Today → My system predicted the BA collapse – now it’s issuing an AI warning (From Chaikin Analytics) (Ad) Free NPCE Stock Alerts $8.51 -0.01 (-0.12%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 5:16 PM | finance.yahoo.comNeuroPace to Participate in Two Healthcare Conferences in MayMay 13 at 8:39 PM | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call TranscriptMay 13 at 4:44 AM | americanbankingnews.comCantor Fitzgerald Reiterates "Overweight" Rating for NeuroPace (NASDAQ:NPCE)May 13 at 1:52 AM | americanbankingnews.comLeerink Partnrs Weighs in on NeuroPace, Inc.'s Q2 2024 Earnings (NASDAQ:NPCE)May 12 at 3:50 AM | americanbankingnews.comNeuroPace, Inc. (NASDAQ:NPCE) to Post FY2028 Earnings of $0.27 Per Share, Leerink Partnrs ForecastsMay 10, 2024 | finance.yahoo.comNeuroPace Inc (NPCE) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Ongoing ChallengesMay 10, 2024 | marketbeat.comResearch Analysts Issue Forecasts for NeuroPace, Inc.'s FY2028 Earnings (NASDAQ:NPCE)NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Leerink Partnrs dropped their FY2028 earnings per share (EPS) estimates for shares of NeuroPace in a note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings per share of $0.27 fMay 10, 2024 | markets.businessinsider.comNeuroPace’s Strong Q1 Performance and Promising Growth Prospects Affirm Buy RatingMay 9, 2024 | marketbeat.comTrading was temporarily halted for "NPCE" at 09:05 AM with a stated reason of "LULD pause."May 9, 2024 | finanznachrichten.deNeuroPace, Inc: NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | finance.yahoo.comNeuroPace Inc (NPCE) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ...May 9, 2024 | americanbankingnews.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 8, 2024 | msn.comNeuroPace GAAP EPS of -$0.32May 8, 2024 | globenewswire.comNeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | markets.businessinsider.comNeuroPace is about to announce its earnings — here's what Wall Street expectsMay 5, 2024 | americanbankingnews.comOrbimed Advisors Llc Sells 4,674 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockMay 5, 2024 | americanbankingnews.comOrbimed Advisors Llc Sells 15,690 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockMay 4, 2024 | insidertrades.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 4,674 Shares of StockApril 27, 2024 | insidertrades.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 1,781 SharesApril 24, 2024 | insidertrades.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $345,756.45 in StockApril 23, 2024 | marketbeat.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 24,609 Shares of StockNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 24,609 shares of the stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $14.05, for a total value of $345,756.45. Following the sale, the insider now owns 3,459,113 shares in the company, valued at approximately $48,600,537.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.April 20, 2024 | investing.comOrbiMed Advisors sells shares in NeuroPace worth over $238,000April 19, 2024 | insidertrades.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 2,623 Shares of StockApril 18, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $36,879.38 in StockNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 2,623 shares of the company's stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $14.06, for a total transaction of $36,879.38. Following the sale, the insider now directly owns 3,501,975 shares in the company, valued at $49,237,768.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.April 17, 2024 | globenewswire.comNeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024April 16, 2024 | insidertrades.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $6,692,916.51 in StockApril 15, 2024 | marketbeat.comOrbimed Advisors Llc Sells 461,899 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 461,899 shares of the firm's stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $14.49, for a total value of $6,692,916.51. Following the completion of the sale, the insider now owns 3,542,068 shares in the company, valued at $51,324,565.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.April 14, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy ratApril 12, 2024 | marketbeat.comShort Interest in NeuroPace, Inc. (NASDAQ:NPCE) Grows By 178.0%NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 85,900 shares, a growth of 178.0% from the March 15th total of 30,900 shares. Currently, 0.7% of the company's shares are short sold. Based on an average trading volume of 98,900 shares, the short-interest ratio is currently 0.9 days.April 10, 2024 | fool.comNeuroPace (NASDAQ: NPCE)April 6, 2024 | marketbeat.comKent Lake Capital LLC Buys 96,529 Shares of NeuroPace, Inc. (NASDAQ:NPCE)Kent Lake Capital LLC grew its stake in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 670,946 shares of the company's stock after acquiring an additional 96,529 shares during theApril 4, 2024 | msn.com'Biggest mistake' bond investors may make ahead of Fed rate cutsMarch 27, 2024 | globenewswire.comNeuroPace to Present at the Needham 23rd Annual Healthcare ConferenceMarch 20, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Recommendation of "Moderate Buy" by BrokeragesNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have assigned a buMarch 14, 2024 | marketbeat.comNeuroPace (NASDAQ:NPCE) Raised to Overweight at Wells Fargo & CompanyWells Fargo & Company raised shares of NeuroPace from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $16.00 to $20.00 in a report on Thursday.March 14, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Short Interest Down 19.8% in FebruaryNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 29th, there was short interest totalling 50,300 shares, a decrease of 19.8% from the February 14th total of 62,700 shares. Based on an average daily trading volume, of 86,100 shares, the short-interest ratio is currently 0.6 days. Currently, 0.4% of the shares of the company are short sold.March 13, 2024 | markets.businessinsider.comThe Latest Analyst Ratings For NeuroPaceMarch 9, 2024 | marketbeat.comFmr LLC Trims Stock Holdings in NeuroPace, Inc. (NASDAQ:NPCE)Fmr LLC decreased its stake in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 42.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 706,245 shares of the company's stock after sellingMarch 8, 2024 | marketbeat.comQ1 2024 Earnings Estimate for NeuroPace, Inc. (NASDAQ:NPCE) Issued By Leerink PartnrsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Equities research analysts at Leerink Partnrs increased their Q1 2024 earnings per share (EPS) estimates for NeuroPace in a research report issued to clients and investors on Tuesday, March 5th. Leerink Partnrs analyst M. Kratky now forecasts that theMarch 7, 2024 | markets.businessinsider.comNeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth DriversMarch 7, 2024 | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comNeuroPace Full Year 2023 Earnings: EPS Beats ExpectationsMarch 7, 2024 | marketbeat.comResearch Analysts Set Expectations for NeuroPace, Inc.'s Q1 2025 Earnings (NASDAQ:NPCE)NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of NeuroPace in a note issued to investors on Tuesday, March 5th. Leerink Partnrs analyst M. Kratky anticipates that the company will post earnings per share of ($1.25) forMarch 7, 2024 | seekingalpha.comNeuroPace, Inc. (NPCE) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | benzinga.comRecap: NeuroPace Q4 EarningsMarch 6, 2024 | msn.comNeuroPace GAAP EPS of -$0.23March 6, 2024 | markets.businessinsider.comNeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending ConcernsMarch 5, 2024 | globenewswire.comNeuroPace Announces Record Full Year 2023 Revenue of $65.4 MillionMarch 5, 2024 | investorplace.comFinancial Freedom Fighters: 3 Stocks to Liberate Your PortfolioFebruary 24, 2024 | msn.comNeuroPace (NPCE) Price Target Increased by 27.95% to 15.01 Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Millionaire Says: “Buy This $11 AI Coin.” (Ad)Right now, you can harness the power of two bull markets... Artificial intelligence...And cryptos. Find out more about this $11 AI Coin right now NPCE Media Mentions By Week NPCE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NPCE News Sentiment▼0.410.57▲Average Medical News Sentiment NPCE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NPCE Articles This Week▼232▲NPCE Articles Average Week Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Pulmonx News Bioventus News Anika Therapeutics News Beauty Health News Pulse Biosciences News Tactile Systems Technology News Cerus News Nevro News OraSure Technologies News Surmodics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NPCE) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsAmerica’s worst nightmare?Porter & CompanyInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperHow to Make 100X on the AI BoomInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
